The DCGI now suspends the license of the Parenteral Surgical India Pvt Ltd. after using the contaminated IV fluids at Jodhpur hospitals. It has also sent the notice to the company for violating rules and will take further action only after the detailed report on the samples that were sent to the Central Drugs Laboratory, Kolkata. The decision is expected to be done by March 15 as per Health Secretary K Chandramouli. An official also mentioned that the case will be presented by the Drug and Cosmetics Act in 10 days along with laboratory reports. The Indore-based Parenteral Surgical India Pvt Ltd along with drug inspectors from Mumbai and MP had submitted a detailed report on the condition earlier. The possibility is that the products are being manufactured of sub standard quality. The whole unit was not following the good manufacturing practice leading to a tragedy. The temperature and humidity was not controlled in some areas leading to problem in manufacturing. The deaths was caused due to the administration of dextrose and compound sodium lactate injections as they were stored in freeze stocks of large volume parenterals (LVPS) manufactured by Parenterals Surgicals Limited worth Rs 1.35 crore.